Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Targeted therapies could treat a broad range of cancers: Research

Targeted therapies could treat a broad range of cancers: Research

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Amorfix second quarter net loss decreases to $25,728

Amorfix second quarter net loss decreases to $25,728

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

People with SLE more likely to develop hematologic malignancies

People with SLE more likely to develop hematologic malignancies

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Celsion receives $244,000 grant under QTDP program

Celsion receives $244,000 grant under QTDP program

Liver-related mortality ranks #4 for people between ages of 45 and 64

Liver-related mortality ranks #4 for people between ages of 45 and 64

H. pylori infection reduces severity of Salmonella-induced colitis: Research

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

‘Off the shelf’ new livers from stem cells, glimmer of hope

‘Off the shelf’ new livers from stem cells, glimmer of hope

Study suggests curcumin may be an effective therapy for liver fibrosis

Study suggests curcumin may be an effective therapy for liver fibrosis

£600 million cancer drug fund for UK cancer patients

£600 million cancer drug fund for UK cancer patients

HIFU technology effective for treating metastatic liver cancer

HIFU technology effective for treating metastatic liver cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.